Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology - 1 Aug 2010

Gadducci Angiolo, Biglia Nicoletta, Cosio Stefania, Sismondi Piero, Genazzani Andrea Riccardo

Abstract excerpt

BRCA1 and BRCA2 mutation carriers have a 54-85% and 45% lifetime risk of developing breast cancer, respectively, and a 18-60% and 11-27% lifetime risk of developing ovarian cancer, respectively. Oral contraceptives (OCs) significantly reduce the risk of ovarian cancer also in BRCA1/BRCA2 mutation carriers. The association between OC use and breast cancer risk in these women is controversial. Some studies showed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Contraceptives, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Replacement Therapy

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Mutation

Share to Ovarian Neoplasms

Share to Ovariectomy

Source

Identifiers

PMID: 20632911
DOI: 10.3109/09513590.2010.487609

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.PMID 20632911Read ↗

BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.Semantic proximity Read ↗

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.Semantic proximity Read ↗

Reproductive Issues for Women With BRCA MutationsSemantic proximity Read ↗

Managing hereditary ovarian cancer.Semantic proximity Read ↗

The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.Semantic proximity Read ↗

Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.Semantic proximity Read ↗

Management problems. BRCA mutation, prophylactic oophorectomy and HRT.Semantic proximity Read ↗

Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.Semantic proximity Read ↗

Genital Cancers in Women: Ovarian Cancer.Semantic proximity Read ↗

Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK.Semantic proximity Read ↗

Hormone replacement therapy in BRCA mutation carriers: how shall we do no harm?Semantic proximity Read ↗

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.